ScoreWhy is Fredun Pharmaceuticals Ltd ?
1
Healthy long term growth as Net Sales has grown by an annual rate of 39.73% and Operating profit at 55.03%
2
With a growth in Operating Profit of 99.09%, the company declared Very Positive results in Dec 25
- The company has declared positive results for the last 7 consecutive quarters
- NET SALES(Q) At Rs 160.93 cr has Grown at 56.70%
- PBT LESS OI(Q) Highest at Rs 14.00 cr.
- PBDIT(Q) Highest at Rs 26.34 cr.
3
With ROCE of 20.2, it has a Attractive valuation with a 3.5 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 143.19%, its profits have risen by 63.5% ; the PEG ratio of the company is 0.8
4
Increasing Participation by Institutional Investors
- Institutional investors have increased their stake by 2.33% over the previous quarter and collectively hold 3.94% of the company
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors
5
Market Beating performance in long term as well as near term
- Along with generating 143.19% returns in the last 1 year, the stock has outperformed BSE500 in the last 3 years, 1 year and 3 months
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Fredun Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Fredun Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Fredun Pharma
143.19%
3.13
45.75%
Sensex
9.01%
0.78
11.54%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
39.73%
EBIT Growth (5y)
55.03%
EBIT to Interest (avg)
2.55
Debt to EBITDA (avg)
2.89
Net Debt to Equity (avg)
1.03
Sales to Capital Employed (avg)
1.65
Tax Ratio
22.33%
Dividend Payout Ratio
2.11%
Pledged Shares
0
Institutional Holding
3.94%
ROCE (avg)
14.74%
ROE (avg)
13.09%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
33
Industry P/E
24
Price to Book Value
6.13
EV to EBIT
17.45
EV to EBITDA
16.11
EV to Capital Employed
3.53
EV to Sales
2.11
PEG Ratio
0.77
Dividend Yield
0.03%
ROCE (Latest)
20.23%
ROE (Latest)
18.34%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
Mildly Bullish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend29What is working for the Company
NET SALES(Q)
At Rs 160.93 cr has Grown at 56.70%
PBT LESS OI(Q)
Highest at Rs 14.00 cr.
PBDIT(Q)
Highest at Rs 26.34 cr.
OPERATING PROFIT TO NET SALES(Q)
Highest at 16.37%
PAT(Q)
Highest at Rs 10.48 cr.
EPS(Q)
Highest at Rs 22.20
-7What is not working for the Company
INTEREST(Q)
Highest at Rs 10.55 cr
Loading Valuation Snapshot...
Here's what is working for Fredun Pharma
Profit Before Tax less Other Income (PBT) - Quarterly
At Rs 14.00 cr has Grown at 96.35%
Year on Year (YoY)MOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Profit After Tax (PAT) - Quarterly
At Rs 10.48 cr has Grown at 96.6%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Net Sales - Quarterly
At Rs 160.93 cr has Grown at 56.70%
Year on Year (YoY)MOJO Watch
Near term sales trend is very positive
Net Sales (Rs Cr)
Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 14.00 cr. and Grown
each quarter in the last five quartersMOJO Watch
Near term PBT trend is very positive
PBT less Other Income (Rs Cr)
Operating Profit (PBDIT) - Quarterly
Highest at Rs 26.34 cr.
in the last five quartersMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (Rs Cr)
Operating Profit Margin - Quarterly
Highest at 16.37%
in the last five quartersMOJO Watch
Company's efficiency has improved
Operating Profit to Sales
Profit After Tax (PAT) - Quarterly
Highest at Rs 10.48 cr.
in the last five quartersMOJO Watch
Near term PAT trend is positive
PAT (Rs Cr)
Earnings per Share (EPS) - Quarterly
Highest at Rs 22.20
in the last five quartersMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (Rs)
Here's what is not working for Fredun Pharma
Interest - Quarterly
At Rs 10.55 cr has Grown at 36.48%
Quarter on Quarter (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
Interest - Quarterly
Highest at Rs 10.55 cr
in the last five quarters and Increased by 36.48 % (QoQ)MOJO Watch
Rising interest cost signifies increased borrowings
Interest Paid (Rs cr)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
